Top Markets
Coin of the day
Aeglea BioTherapeutics, Inc. Aeglea BioTherapeutics, Inc.

Aeglea BioTherapeutics, Inc.

AGLE
株式のランク #23495
Aeglea BioTherapeutics, Inc. is a clinical-stage biotechnology firm dedicated... Aeglea BioTherapeutics, Inc. is a clinical-stage biotechnology firm dedicated to creating human enzyme therapies for rare metabolic diseases. Their leading candidate, pegzilarginase, a recombinant human Arginase 1, is currently in the pivotal Phase III PEACE trial to assess its safety and effectiveness for treating Arginase 1 deficiency. Furthermore, the company is developing AGLE-177, a polyethylene glycol modified enzyme, which is progressing through Phase I/II clinical trials for homocystinuria. Their early-stage pipeline includes AGLE-325 for cystinuria, along with other ongoing research initiatives. Founded in 2013, the company was initially known as Aeglea BioTherapeutics Holdings, LLC, changing its name to Aeglea BioTherapeutics, Inc. in March 2015. It is based in Austin, Texas.
株価
$19.30
最終同期: 2023-12-26
時価総額
$72.77M
変化(1日)
6.22%
変化(1年)
0.00%
US
取引 Aeglea BioTherapeutics, Inc. (AGLE)

カテゴリー

Aeglea BioTherapeutics, Inc.(AGLE)の株価履歴
終値の最高値: $17.81 (2023-12-01)

終値の最安値: $240.00 (2016-04-01)
Aeglea BioTherapeutics, Inc. の株価履歴(2016 ~ 2026)
年間株価パフォーマンス
パフォーマンス
2023 80.43%
2022 -90.79%
2021 -48.55%
2020 6.06%
2019 3.25%
2018 49.19%
2017 -3.90%
2016 0.00%
類似企業または競合の株価
企業 株価 変化率 1年%
$547.71 38.62%
US
$1.04K 58.06%
NL
$145.75 437.43%
US
$118.70 -15.60%
AU
$770.19 8.98%
CH